GRAL

$68.56-$2.58 (-3.63%)prev close

Compare

Held by

portfolio on TandT

Bookmarked by

users

Avg position size

0.0%

of holders' portfolios

13F filers

institution

Market cap

$2.9B

43M shares

52-week range

$29.95 – $118.84

43% from low

Sector

SERVICES-MEDICAL LABORATORIES

Exchange

NASDAQ

Change+$51.56

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$179M	+21.6%	$-10.33	$-10.47–$-10.17	—	5
2027	$223M	+25.1%	$-10.62	$-11.01–$-10.17	—	5
2028	$286M	+28.2%	$-10.07	$-13.33–$-7.95	—	8
2029	$378M	+31.8%	$-10.57	$-12.13–$-9.44	—	6

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 6 of the last 7 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-05-05	$-2.76	$-2.29	+17.1%
2026-02-19	$-3.33	$-2.44	+26.7%
2025-11-12	$-3.36	$-2.46	+26.8%
2025-08-12	$-3.14	$-3.18	-1.3%
2025-05-13	$-4.03	$-3.10	+23.1%
2025-02-20	$-4.41	$-1.86	+57.8%
2024-11-12	$-6.43	$-3.94	+38.7%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
GRALGRAIL Inc.	$68.56	-3.63%	$2.9B	—
AAPGAscentage Pharma Group International	$17.43	-3.57%	$1.6B	—
APGEApogee Therapeutics, Inc.	$134.09	-0.16%	$8.3B	—
CELCCelcuity Inc.	$86.38	-1.44%	$4.2B	—
CNTACentessa Pharmaceuticals plc	$40.50	+0.00%

GRAIL, Inc. Common Stock

GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.

www.grail.com

Employees: 910
IPO / List date: Jun 12, 2024
HQ: MENLO PARK, CA

Held by traders on TradeandTell

Trader / Portfolio	Conviction
RH Individual Liam	—

Super investors & insiders

Institutions holding (13F)

Institution	Shares	Reported
Renaissance Technologiesas of 2026-03-31	55,200	$2.9M

Insider activity (SEC Form 4)

Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.

Insider activity (SEC Form 4)

People who hold GRAL also hold

GGR

Gogoro Inc. Ordinary Shares

1 co-holder · 100% overlap

LNSR

LENSAR, Inc. Common Stock

1 co-holder · 100% overlap

BMBL

Bumble Inc. Class A Common Stock

1 co-holder · 100% overlap

DXYZ

Destiny Tech100 Inc.

1 co-holder · 100% overlap

DDI

DoubleDown Interactive Co., Ltd. American Depository Shares

1 co-holder · 100% overlap

SFM

Sprouts Farmers Market, Inc.

1 co-holder · 100% overlap

Ranked by collective conviction (sum of co-holders' % allocation) across public portfolios holding GRAL.

Recent trades on TradeandTell

LiamBUY@ $68.39
6/30/2026
in RH Individual →

$GRAL chatter on StockTwits

Danny@DannyGh8stBullish6d
$GRAL Has a Potential growth from successful clinical validation and adoption..
View on StockTwits ↗
Noah@NoahMiles11BullishJul 25
$GRAL
View on StockTwits ↗
11th.com@11thestateJul 16
If you're a $GRAL investor, there's a case you should know about. We have all the details, including how to join the case and stay informed about any potential recovery. Check it out: https://11th.com/cases/grail-investor-suit
View on StockTwits ↗
karen@gobioJul 16
$GRAL GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced a collaboration with Priority Health, a nationally recognized nonprofit health plan and the third largest provider-sponsored health plan in the nation, to make GRAIL's Galleri® multi-cancer early detection (MCED) test available to Priority Health's self-insured employer groups. Priority Health launched coverage for Galleri in its Thrive and Thrive Plus Medicare Advantage plans in 2025 and is expanding on its partnership with GRAIL to become the first Michigan health plan to enable its employer groups to easily add the Galleri test to their existing cancer screening coverage.
View on StockTwits ↗
Alfons Morris@juracquis13Jul 13
https://stocktwits.com/news-articles/markets/equity/why-is-gral-stock-down-today-analysts-lower-targets-after-uk-trial-setback-selloff-overdone/cZRN5uHR4x9 $GRAL I wouldn't pay $10K for a cybertruck.
View on StockTwits ↗
Billioner@BillionerOfKingJul 9
$GRAL Current Stock Price: $75.84 Contracts to trade: $75.0 GRAL Jul 17 2026 Call Entry: $1.75 Exit: $2.90 ROI: 66% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
View on StockTwits ↗
Nicholas@JFDIJul 9
even the holy $GRAL curling up off the beat down
View on StockTwits ↗
Matthew Joseph@BinaryLogicBullishJun 23
$GRAL just made news on NPR for its Galleri test pending FDA approval at the close of the year. GRAL has a market cap of $2.7B. While the Galleri test is pioneering liquid biopsy technology, it is relatively expensive $1000, long-lead and limited to specialized technical labs. Contrast that with $VNRX CaptureSeq which shows comparable specificity, but outstanding detection of Phs-1/2 cancers at a fraction of the cost using technology at nearly any/all hospitals worldwide. IP secured to 2044 and market cap of $12M, grossly Oversold and in discussions with all leading liquidity biopsy/diagnostic Companies globally on licensing agreements. https://www.npr.org/2026/06/21/nx-s1-5858691/blood-test-multi-cancer-early-detection-mced
View on StockTwits ↗
Bonnie Winter@bonniewinterJun 16
$GRAL looks like Goldman Sachs $60PT has places a lid on the share price. Grails’s MCED test Galleri is being adopted well with private payors and Tricare. Revenue is exceeding expectations each quarter. All clinical trials including Pathfinder 2 and UK NHS trial have confirmed superior clincial validity which is the main basis for FDA approval. Regarding clinical utility, they showed a remarkable 20% improvement in delaying progression to Stage 4 cancers and have commenced the REACH trial with Medicare patients to confirm this finding from the UK trial. The Medical Oncology community and cancer patients are elated about early detection and early interventions for many cancers which still do not have any primary screening. Bill Gates & Jeff Bezos remain large shareholders of this industry disruptor technology, the first of its kind which will achieve FDA APPROVAL soon.
View on StockTwits ↗
SJ@BazzzigarBearishJun 9
$GRAL moved to MANE
View on StockTwits ↗
TheUnmaker@TheUnmakerBullishJun 9
$TNXP $GRAL $CCCC $QSI
View on StockTwits ↗
Ripster , Tenet Trade Group@ripster47Jun 5
$GRAL | Goldman Sachs Starts GRAIL, Inc. PT to $60 on Regulatory Milestones Goldman Sachs initiates coverage as FDA approval, CMS coverage, and MCED adoption remain key growth determinants 🔹 Follow @tenet_research for more analyst insights on other tickers.
View on StockTwits ↗
Katherine Lewis@LewisDaKatJun 5
$GRAL GRAL Price Target Alert: $60.00. Issued by Goldman Sachs https://marketwirenews.com/stock/gral/news/gral-price-target-alert-60-00-issued-by-goldman-sach-7221385765324160.html?utm_source=stocktwits
View on StockTwits ↗
Katherine Lewis@LewisDaKatJun 5
$GRAL Neutral Recommendation Issued On GRAL By Goldman Sachs https://marketwirenews.com/stock/gral/news/neutral-recommendation-issued-on-gral-by-goldman-sac-6688585928039035.html?utm_source=stocktwits
View on StockTwits ↗
karen@gobioJun 5
$GRAL https://www.statnews.com/2026/06/04/grail-multi-cancer-early-detection-test-trial-results/?utm_campaign=daily_recap&utm_medium=email&_hsenc=p2ANqtz-9ialr9z14UWDBeQ8mfefa1-B9rldpk8RJlOBPw4bFeO1wzj9_XIlVsit_cYS7grXgyiESn2M_IvnEBocosqAh9eq4knw&_hsmi=422308760&utm_content=422308760&utm_source=hs_email
View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.